newsfilter
← Latest News
Business Wire·

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Innate Pharma SA executives will attend the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14–16, 2026.
  • The company's fireside chat is scheduled for September 14, 2026, at 4:30 PM EDT (10:30 PM CEST).
  • A live webcast of the event will be available via the Investors section of Innate Pharma's website, with a replay to follow.
  • Innate Pharma is a clinical-stage biotechnology firm focused on developing immunotherapies, including antibody-drug conjugates (ADCs).
  • The company's lead clinical asset is IPH4502, a Nectin-4 ADC for solid tumors, supported by a preclinical ADC portfolio.
  • Innate Pharma is advancing two partnered late-stage assets: lacutamab with Sobi for cutaneous T-cell lymphomas & monalizumab with AstraZeneca for non-small cell lung cancer.
  • The company maintains collaborations with Sobi, Sanofi, & AstraZeneca to advance immuno-oncology innovation.
  • Innate Pharma is headquartered in Marseille, France, & trades on Euronext Paris (IPH) & Nasdaq (IPHA).